
# **Head and Neck Cancers**


# 《 Cancer of the oral cavity-1 》



\*2 no pathologic risk factor:T1-T2,N1  $\rightarrow$  OBS or RT note:PNI alone in early stage(stage I  $\cdot$  II) selective treatment

\*3 consider re-resection to achieve negative margins for positive resection margins if feasible

\* Pathological(first)/Image Finding



#### 137\_



# 《 Oral cavity 》

 Work-Up
 Necessary examination

 • Biopsy
 • Chest radiography

 • H&N MRI or CT
 • Whole body bone scan (optional if early stage)


 • Abdomen sonography
 • Dental consultation (prior to R/T)

 • Dietician consultation
 • Speech & swallowing evaluation)


 • ENT consultation
 • Screening for hepatits B

 • PET-CT for stage III-IV disease
 • Panendoscopy (if smoking or drinking wine)


# 《 Cancer of the Hypopharynx -1 》



# 《 Cancer of the Hypopharynx -2 》



# 《 Cancer of the Hypopharynx -3 》




Elective neck dissection for Large(  $\geq$  6cm)  $\pm$  central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

\* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion


\* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

\* Pathological(first)/Image Finding

# 《 Cancer of the Oropharynx -1 》



# 《 Cancer of the Oropharynx -2 》




Elective neck dissection for Large ( $\geq 6$  cm)  $\pm$  central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

\* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

\* 2 consider re-resection to achieve negative margins for positive resection margins if feasible


\* Pathological(first)/Image Finding

# 《 Cancer of the Glottic Larynx-1 》




144

# 《 Cancer of the Glottic Larynx -2 》



<sup>\*</sup> Pathological(first)/Image Finding

# 《 Cancer of the Glottic Larynx -3 》




Elective neck dissection for Large(  $\geq$  6cm)  $\pm$  central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

\* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion \*

\* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

\*Pathological(first)/Image Finding

# 《 Cancer of the Nasopharynx -1 》



147



# 《 follow up recommendation 》

Follow-up frequency

- Every month in the 1st year after treatment
- Every 2-3 months in the 2nd year after treatment
- Every 3 months in the 3rd year after treatment
- Every 6 months in the 4th-5th year after treatment

#### H&N MRI or CT

- Every 3-6 months within the first 3 years after treatment
- Every 6-12 months beyond 3 years after treatment

#### Whole body bone scan

- Every 3-6 months within the first 3 years after treatment
- Every 6-12 months beyond 3 years after treatment

#### Abdomen sonography

- Every 3-6 months within the first 3 years after treatment
- Every 6-12 months beyond 3 years after treatment

### PET and Whole body bone scan and Panendoscopy

• If indicated clinically

# 《 Reference 》

- 1. Al-Sarrf M, LeBlanc M, Giri PG, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer : phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-1317.Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.J Clin Oncol 2005; 23 : 6730-6738.
- 2. NCCN Head abd Neck Cancer Guidelines Version 5,2024
- 3. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.N Engl J Med 2004; 350:1945-1952.
- 4. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6 : 28-38.
- 5. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.J Natl Cancer Inst 2005; 97: 536-539.
- 6. Chan ATC, Hsu M-M, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or meta tatic nasopharyngeal carcinoma.J Clin Oncol 2005; 23: 3568-3576.
- 7. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcfinoma of the head and neck.N Engl J Med 2004; 350(19) : 1937-1944.
- 8. Hartford AC, Palosca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO)and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT).Int J Radiat Oncol Biol Phys 2009; 73: 9-14.

